Shift in Antitrust Policy on Pharmacy Benefit Managers and Healthcare Costs
In recent developments, U.S. antitrust authorities under President Donald Trump's administration have shown a distinct inclination towards settling cases with key players in the healthcare sector, particularly pharmacy benefit managers (PBMs). This marks a shift from previous administrations, opting for regulatory settlements over litigation.
A prominent case involves the Federal Trade Commission (FTC) lawsuit against the 'Big Three' PBMs: Optum Inc., Express Scripts Inc., and Caremark LLC, a CVS Health Corp subsidiary. The FTC alleges these entities manipulated pharmaceutical supply chain competition. All three PBMs are either settling or negotiating, marking a departure from strategies during President Joe Biden's administration. Nicholas Cheolas, a partner at Wiley Rein, observed the focus on settlements for both mergers and non-mergers as a key element of this administration's approach.
PBMs serve as critical intermediaries in the healthcare sector, managing prescription drug benefits for health plans and negotiating drug prices. As agents for insurers and consumers, they significantly influence healthcare costs. Recent FTC studies during Lina Khan's tenure have highlighted issues like preferential treatment impacting drug availability for independent pharmacies, increasing scrutiny on the industry's vertical integration.
A notable settlement involves Express Scripts, requiring that the PBM avoid prioritizing higher-cost formularies over cheaper options and ensuring consumer out-of-pocket expenses are based on net drug prices. These reforms aim to curb spread pricing practices and enhance pricing transparency, as noted by Renzo Luzzatti of US-Rx Care. This settlement is expected to influence how employers and buyers evaluate PBM services, although its impact on profit margins is yet to be fully understood.
The shift towards resolving antitrust issues through settlements reflects a broader trend during Trump's tenure, distinguishing the current administration's policy from the proactive judicial engagements of its predecessor. The Department of Justice (DOJ) continues its commitment to antitrust enforcement, emphasizing resource efficiency and immediate consumer relief through settlements.
Although the administration appears open to settlements, this does not suggest leniency in enforcement. The DOJ remains focused on crucial economic segments affecting consumers, emphasizing timely results through available mechanisms. Notably, the mixed effects of these settlements on consumer protection include provisions extending beyond core antitrust concerns. Kathleen Bradish of the American Antitrust Institute suggests that some settlement provisions might reflect administrative priorities, potentially influencing broader regulatory objectives.